118313-35-2

Basic information

• Product Name: 5-METHOXY-2H-ISOQUINOLIN-1-ONE
• Synonyms: 5-METHOXY-2H-ISOQUINOLIN-1-ONE;5-methoxyisoquinolin-1(2H)-one
• CAS NO: 118313-35-2
• Molecular Formula: C10H9NO2
• Molecular Weight: 175.186
• Mol File: 118313-35-2.mol

Chemical Properties

• Melting Point: 222-224 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 438.478°C at 760 mmHg
• Flash Point: 218.984°C
• Appearance: /
• Density: 1.199g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.574
• PKA: 12.79±0.20(Predicted)
• CAS DataBase Reference: 5-METHOXY-2H-ISOQUINOLIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-2H-ISOQUINOLIN-1-ONE(118313-35-2)
• EPA Substance Registry System: 5-METHOXY-2H-ISOQUINOLIN-1-ONE(118313-35-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 118313-35-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-METHOXY-2H-ISOQUINOLIN-1-ONE is used as a potential antioxidant for its ability to combat oxidative stress, which is implicated in various diseases and aging processes.
5-METHOXY-2H-ISOQUINOLIN-1-ONE is used as a potential anti-inflammatory agent for its capacity to reduce inflammation, which is a common factor in many chronic conditions.
Used in Neuroprotective Applications:
5-METHOXY-2H-ISOQUINOLIN-1-ONE is used as a neuroprotective agent for its potential to shield neurons from damage, which could be beneficial in the treatment of neurodegenerative diseases.
5-METHOXY-2H-ISOQUINOLIN-1-ONE is used as a candidate for the treatment of neurodegenerative diseases due to its potential to mitigate the progression of such conditions through its neuroprotective properties.
Note: The uses listed are based on the potential properties of 5-METHOXY-2H-ISOQUINOLIN-1-ONE as described in the provided materials. Actual applications may vary and are subject to ongoing research and development.

InChI:InChI=1/C10H9NO2/c1-13-9-4-2-3-8-7(9)5-6-11-10(8)12/h2-6H,1H3,(H,11,12)

Upstream product

• 1711-05-3 m-anisoyl chloride 
• 586-38-9 3-Methoxybenzoic acid 
• 108-05-4 vinyl acetate 
• 1414350-91-6 3-methoxy-N-(pivaloyloxy)benzamide 
• 5154-02-9 isoquinoline-1,5-diol 
• 1011-54-7 2-methoxycinnamic acid 
• 74-88-4 methyl iodide 
• 118652-95-2 3-(2-methoxy-phenyl)-acryloyl azide 

Downstream Products

• 1432725-78-4 (2-bromo-5-trifluoromethylphenyl)(5-methoxyisoquinolin-1-yl)methanone 
• 1432725-76-2 (2-bromo-4,5-dimethoxyphenyl)(5-methoxyisoquinolin-1-yl)methanone 
• 1432725-75-1 (2-bromophenyl)(5-methoxyisoquinolin-1-yl)methanone 
• 1432725-61-5 (2-bromo-5-trifluoromethylphenyl)(5-methoxyisoquinolin-1-yl)-acetonitrile 
• 1432725-56-8 (2-bromo-4,5-dimethoxyphenyl)(5-methoxyisoquinolin-1-yl)-acetonitrile 
• 1432725-54-6 (2-bromophenyl)(5-methoxyisoquinolin-1-yl)acetonitrile 
• 106462-85-5 1-chloro-5-methyoxyisoquinoline 

Relevant articles and documents

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Rhodium(III)-catalyzed C-H activation/annulation with vinyl esters as an acetylene equivalent

The behavior of electron-rich alkenes in rhodium-catalyzed C-H activation/annulation reactions is investigated. Vinyl acetate emerges as a convenient acetylene equivalent, facilitating the synthesis of sixteen 3,4-unsubstituted isoquinolones, as well as select heteroaryl-fused pyridones. The complementary regiochemical preferences of enol ethers versus enol esters/enamides is discussed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula (I) wherein A, R2, R3, R', B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process

The invention is selected, novel, and known analogs of isoquinolinones of the formula and pharmaceutically acceptable salts thereof; novel pharmaceutical compositions; and a method for enhancing the lethal effects for tumor cells to treatment having DNA damaging activity such as ionizing radiation or with chemotherapeutic agents.